INNOVUS PHARMACEUTICALS, INC. - FORM 10-K - EX-32.1 - CERTIFICATION - March 30, 2016

Attached files

file filename
EX-14.1 - CODE OF ETHICS - INNOVUS PHARMACEUTICALS, INC.ex_141.htm
10-K - ANNUAL REPORT - INNOVUS PHARMACEUTICALS, INC.innv_dec312015.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - INNOVUS PHARMACEUTICALS, INC.ex_211.htm
EX-31.2 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_312.htm
EX-23.2 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_232.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - INNOVUS PHARMACEUTICALS, INC.ex_231.htm
EX-31.1 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_311.htm
Exhibit 32.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Innovus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bassam Damaj, principal executive officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that:
 
1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
2.          The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.
 
 
March 30, 2016
/s/ Bassam Damaj
 
Bassam Damaj
 
President and Chief Executive Officer
 
(Principal Executive Officer)
 
 
In connection with the Annual Report of Innovus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bassam Damaj, principal financial and accounting officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that:
 
1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
2.          The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.
 
 
March 30, 2016
/s/ Bassam Damaj
 
Bassam Damaj
 
(Principal Financial and Accounting Officer)
 
  


INNOVUS PHARMACEUTICALS, INC. Reports